Transplantation for Chagas' disease: an overview of immunosuppression and reactivation in the last two decades.

Authors: Bacal F,Silva CP,Pires PV,Mangini S,Fiorelli AI,Stolf NG,Bocchi EA,
Address: Heart Institute (InCor), University of São Paulo, Medical School - Heart Transplant Unit, São Paulo, Brazil. fbacal@uol.com.br
Journal: Clin Transplant.

Publication: 2010 Mar-Apr;24(2):E29-34. doi: 10.1111/j.1399-0012.2009.01202.x. Epub 2010 Jan 19.

abstract

Over the last 20 yr, the immunosuppression protocols in Chagasic heart-transplanted patients have gone through three phases, and we have identified several changes and discoveries about Chagas' disease reactivation, mortality, and neoplasia development. The first phase was especially important because until that time, Chagas' disease was an absolute contraindication for Transplantation. The second phase started when an adjustment was made to the immunosuppression protocol, a lower dosage being adopted to avoid adverse effects, especially neoplasias and reactivation episodes. Currently, strategies to change the immunosuppression, especially replacement of mycophenolate mofetil by azathioprine or low doses of mycophenolate in this special situation, have been shown to be effective in reducing Chagas' disease reactivation. Cardiac transplantation for Chagas' disease is a reality. Although patients with Chagas' disease may experience particular complications when undergoing transplantation compared with transplantation for other etiologies, these difficulties are well known, and treatment and preventive strategies are also better established. In other organs and tissues, transplantation in patients with Chagas' disease also has good outcomes. Blood monitoring for parasitemias is mandatory as is the institution of therapy in the case of a reactivation diagnosis. Acute Chagas' disease may occur in patients who received organs from donors with Chagas' disease.

Related Articles
Risk factors for Chagas' disease reactivation after heart transplantation.
J Heart Lung Transplant. 2008
Risk factors for Chagas' disease reactivation after heart transplantation.
Campos SV, Strabelli TM, Amato Neto V, Silva CP, Bacal F, Bocchi EA, Stolf NA. J Heart Lung Transplant. 2008 Jun; 27(6):597-602. Epub 2008 Apr 24.
Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment.
J Heart Lung Transplant. 1996
Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment.
Almeida DR, Carvalho AC, Branco JN, Pereira AP, Correa L, Vianna PV, Buffolo E, Martinez EE. J Heart Lung Transplant. 1996 Oct; 15(10):988-92.
Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy.
J Heart Lung Transplant. 2007
Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy.
Marchiori PE, Alexandre PL, Britto N, Patzina RA, Fiorelli AA, Lucato LT, Rosemberg S, Pereira SL, Stolf NG, Scaff M. J Heart Lung Transplant. 2007 Nov; 26(11):1091-6. Epub 2007 Oct 24.
Review Heart transplants for patients with Chagas' heart disease.
Sao Paulo Med J. 1995
Review Heart transplants for patients with Chagas' heart disease.
Bocchi EA. Sao Paulo Med J. 1995 Mar-Apr; 113(2):873-9.
Review Heart transplantation for Chagas' cardiomyopathy.
Ann Thorac Surg. 1995
Review Heart transplantation for Chagas' cardiomyopathy.
Blanche C, Aleksic I, Takkenberg JJ, Czer LS, Fishbein MC, Trento A. Ann Thorac Surg. 1995 Nov; 60(5):1406-8; discussion 1408-9.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.